OPEN ACCESS
©NIJPP
Publications 2024
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY (NIJPP)

Volume 5 Issue 3 2024

https://doi.org/10.59298/NIJPP/2024/5338420

Harnessing Regulatory T Cells for Immune Modulation in Transplantation Tolerance

Awafung Emmanuel Adie[1]

[1]**Department of Biomedical Engineering Kampala International University Uganda**
Email: awafungadie@gmail.com; awafungadie@kiu.ac.ug

ABSTRACT

Regulatory T cells (Tregs) are pivotal in maintaining immune tolerance and preventing allograft rejection in transplantation. This review explores the mechanisms by which Tregs mediate immune modulation and their potential therapeutic applications in promoting transplantation tolerance. Tregs are characterized by the expression of CD4, CD25, and the transcription factor FOXP3, and they play a critical role in suppressing effector T cell responses and promoting an anti-inflammatory environment. Various strategies for harnessing Tregs for transplantation include the expansion of Tregs ex vivo, the induction of Tregs in vivo through various approaches, and the transfer of Tregs into transplant recipients. Furthermore, we discuss the impact of the transplant environment on Treg function, the role of dendritic cells and cytokines in Treg activation, and the significance of gut-derived Tregs in fostering tolerance. Additionally, we address the challenges of using Tregs in clinical settings, including potential risks such as opportunistic infections and malignancies. Ultimately, harnessing Tregs represents a promising avenue for achieving transplantation tolerance and improving long-term graft survival, and ongoing research is crucial for developing effective and safe strategies for clinical application.

Keywords: Regulatory T cells, Transplantation tolerance, Immune modulation, Allograft rejection, Treg therapy

INTRODUCTION

Transplantation is a critical therapeutic option for patients with end-stage organ failure, yet the success of transplantation is often hindered by the immune response leading to allograft rejection [1,2]. The immune system's recognition of transplanted organs as foreign can trigger robust adaptive immune responses, resulting in acute and chronic rejection [3]. Consequently, lifelong immunosuppression is typically required to prevent graft rejection, which increases the risk of infections, malignancies, and other complications [4]. To address these challenges, there is a growing interest in achieving transplantation tolerance, a state in which the immune system accepts the transplanted organ without the need for continuous immunosuppression [4,5]. Regulatory T cells (Tregs) are a specialized subset of T cells that play a fundamental role in maintaining immune tolerance and homeostasis [6]. Characterized by the expression of CD4, CD25, and the transcription factor FOXP3, Tregs can suppress effector T cell activation, inhibit pro-inflammatory cytokine production, and promote the development of an immunosuppressive microenvironment [7]. Their capacity to modulate immune responses makes Tregs an attractive target for therapeutic strategies aimed at promoting transplantation tolerance [8].

The concept of harnessing Tregs for transplantation tolerance is supported by a wealth of experimental evidence demonstrating their critical role in preventing allograft rejection [9]. In animal models, the administration of Tregs has been shown to enhance graft survival and induce tolerance, leading to successful long-term transplantation outcomes [10]. Furthermore, the presence of Tregs has been correlated with improved graft survival in human transplant recipients, reinforcing the notion that Tregs can play a protective role in transplantation [11]. This review aims to explore the mechanisms underlying Treg-mediated immune modulation in transplantation and their potential therapeutic applications in promoting tolerance [12,13]. We will discuss the various strategies for harnessing Tregs, the impact of the transplant environment on Treg function, and the challenges that must be addressed to translate these findings into clinical practice.

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

Mechanisms of Treg-Mediated Immune Modulation

Regulatory T cells (Tregs) play a pivotal role in maintaining immune homeostasis and preventing excessive immune responses. Their mechanisms of action involve complex interactions with other immune cells, cytokines, and the overall microenvironment. Understanding these mechanisms is crucial for harnessing Tregs for therapeutic purposes, especially in transplantation [14].

Treg Development and Phenotype

Tregs primarily develop in the thymus, where they undergo a rigorous selection process that ensures self-tolerance and the prevention of autoimmunity. The key transcription factor FOXP3 is essential for Treg development and function; mutations or deficiencies in the FOXP3 gene lead to severe autoimmune diseases in humans, illustrating the critical role of Tregs in immune regulation. Tregs can be classified into two main subtypes: thymus-derived Tregs (natural Tregs) and peripheral Tregs (induced Tregs) [15,16]. Natural Tregs (nTregs) arise during thymic development, where they recognize self-antigens and are positively selected to ensure they can exert regulatory functions without provoking autoimmune responses. In contrast, induced Tregs (iTregs) are generated from conventional CD4+ T cells in peripheral tissues, especially in response to specific cytokines such as TGF-β and IL-2.[17] These iTregs are crucial for modulating immune responses in various contexts, including transplantation and tolerance to commensal microbiota. The flexibility in their generation and the ability to adapt to different environmental cues underscore their significance in maintaining immune balance [18].

Mechanisms of Suppression

Tregs utilize several mechanisms to suppress effector T cell responses and foster an anti-inflammatory environment. Key mechanisms include:

Cytokine Secretion: Tregs produce several immunosuppressive cytokines, such as IL-10, TGF-β, and IL-35. IL-10 is well-known for its ability to inhibit pro-inflammatory cytokine production and downregulate antigen presentation [19]. TGF-β, besides promoting Treg differentiation, can also suppress the proliferation and effector functions of various immune cells, including CD4+ and CD8+ T cells. IL-35, a newer member of the IL-12 family, has been identified as crucial in enhancing Treg stability and suppressive capacity [20].

Metabolic Regulation: Tregs can modulate the metabolic activity of effector T cells by depleting essential nutrients, particularly IL-2, which is vital for T cell proliferation. Tregs can utilize IL-2 more efficiently than conventional T cells, leading to localized deprivation and suppression of effector T cell activity [21]. Additionally, Tregs can produce adenosine, a metabolite that has inhibitory effects on T cell activation and promotes an immunosuppressive environment by binding to adenosine receptors on effector T cells. Cell-Cell Interactions: Tregs exert suppressive effects through direct cell-to-cell interactions. One key interaction involves the surface molecule CTLA-4, which competes with CD28 for binding to CD80/CD86 on antigen-presenting cells (APCs) [22]. This competition reduces co-stimulatory signals essential for T cell activation, leading to diminished effector T cell activation. Other surface molecules, such as PD-1 and LAG-3, also contribute to Treg-mediated inhibition by modulating the signaling pathways in interacting T cells [19].

Dendritic Cell Modulation: Tregs have a profound impact on the function of dendritic cells (DCs), the primary antigen-presenting cells responsible for initiating T cell responses. Tregs can promote a tolerogenic phenotype in DCs, characterized by a reduced ability to activate effector T cells. This modulation occurs through several mechanisms, including direct contact and the secretion of immunosuppressive cytokines, leading to enhanced induction of Tregs and suppression of effector T cell responses [23].

The Role of the Transplant Environment

The transplant environment significantly influences Treg function and survival. The presence of specific cytokines, such as IL-10 and TGF-β, can enhance Treg activity, promoting their proliferation and suppressive functions [24]. In contrast, pro-inflammatory cytokines, like IL-6 and TNF-α, can inhibit Treg function and contribute to the activation of effector T cells. The local microenvironment within the transplant site can dictate the balance between tolerance and rejection, emphasizing the importance of understanding these interactions [6]. Moreover, emerging research suggests that the gut microbiome plays a crucial role in Treg development and function. The composition of gut microbiota can influence the systemic immune environment and Treg-mediated immune modulation, indicating that the overall health and microbial diversity of an individual may impact transplant outcomes. Studies have shown that certain bacterial species can enhance Treg populations, suggesting potential therapeutic avenues involving microbiome manipulation to promote tolerance in transplantation [25]. In conclusion, the mechanisms of Treg-mediated immune modulation are complex and multifaceted, involving a combination of cytokine signaling, metabolic interactions, and direct cell-cell contact. Understanding these mechanisms is essential for developing effective strategies to harness Tregs in clinical applications, particularly for achieving transplantation tolerance and improving graft survival.

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

Strategies for Harnessing Tregs in Transplantation

Ex Vivo Expansion of Tregs

One of the most promising strategies for harnessing regulatory T cells (Tregs) in transplantation is their ex vivo expansion. This process begins with isolating Tregs from the transplant recipient's peripheral blood or tissues [26]. Once isolated, Tregs are expanded in vitro using specific cytokines, primarily interleukin-2 (IL-2), which preferentially stimulates the growth of Tregs over conventional effector T cells. Additionally, incorporating co-stimulatory signals, such as CD28 or anti-CD3 antibodies, can further enhance Treg proliferation and functionality [27]. Preclinical models and early clinical trials have demonstrated the efficacy of ex vivo expanded Tregs in promoting graft survival and reducing rejection rates. For instance, studies have shown that reinfusing expanded Tregs can effectively suppress the activation of effector T cells, leading to enhanced tolerance toward the transplanted organ [28]. However, the clinical application of this strategy is not without challenges. Standardizing protocols for Treg isolation and expansion is critical to ensure consistency in the quality and function of the Treg product [29]. Moreover, maintaining the suppressive function of Tregs during culture is essential, as prolonged expansion can lead to a loss of functionality.

In Vivo Induction of Tregs

In vivo induction of Tregs offers another viable approach for promoting tolerance in transplantation. Low-dose IL-2 therapy has garnered attention for its ability to selectively enhance Treg populations while limiting the activation of effector T cells [30]. This method leverages the preferential utilization of IL-2 by Tregs, thereby promoting their survival and function in the transplant recipient. Additionally, agents like transforming growth factor-beta (TGF-β) and certain retinoic acid derivatives can be employed to enhance the differentiation of naive T cells into Tregs [22]. These strategies aim to create an environment conducive to Treg generation, facilitating long-term graft acceptance.

Treg Transfer Therapy

Treg transfer therapy involves the direct infusion of autologous or donor-derived Tregs into transplant recipients. This approach aims to bolster the existing Treg population, promoting tolerance and potentially leading to long-term graft acceptance without the need for continuous immunosuppression [31]. Experimental models have shown promising results, with Treg infusion resulting in reduced rejection rates and improved graft survival. Ongoing clinical trials continue to evaluate the safety and efficacy of Treg transfer therapy in various transplant settings, paving the way for personalized immunomodulatory strategies in transplantation [8].

Challenges and Limitations

Harnessing regulatory T cells (Tregs) for transplantation tolerance offers promising potential, but several challenges must be addressed. A significant concern is the risk of infections and malignancies associated with prolonged immunosuppression or inadequate immune surveillance. The modulation of the immune response through Treg therapies can dampen the host's ability to fight off infections and may increase the risk of tumorigenesis [32]. Moreover, the complexity of Treg biology, including their functional heterogeneity, poses additional challenges in developing standardized therapeutic approaches. Different subsets of Tregs may exhibit varying levels of suppressive function, and their responses can be influenced by the microenvironment [33]. Ensuring the safety, efficacy, and long-term stability of Treg-based therapies necessitates rigorous preclinical and clinical investigations [34,35]. Furthermore, optimizing protocols for Treg isolation, expansion, and administration remains essential to achieve consistent outcomes across patients. Understanding the long-term effects of Treg therapies on the immune landscape will be critical for ensuring their successful application in clinical transplantation settings. Addressing these challenges will pave the way for the effective use of Treg-based strategies to promote tolerance and improve transplant outcomes.

CONCLUSION

Harnessing regulatory T cells for immune modulation represents a promising strategy for achieving transplantation tolerance. By leveraging the natural immunosuppressive capabilities of Tregs, it is possible to reduce the reliance on conventional immunosuppressive therapies and improve long-term graft survival. Ongoing research efforts are crucial for understanding the intricate mechanisms underlying Treg function, optimizing therapeutic strategies, and translating these findings into clinical practice. Ultimately, the successful application of Treg-based therapies may revolutionize the field of transplantation, providing new avenues for promoting tolerance and enhancing patient outcomes.

REFERENCES

1. Pankaj Chandak, Chris Callaghan, The immunology of organ transplantation, Surgery (Oxford), 2014; 32, (7), 325-332, https://doi.org/10.1016/j.mpsur.2014.04.012.

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

2. Melina Farshbafnadi, Sepideh Razi, Nima Rezaei, Chapter 7 - Transplantation, Editor(s): Nima Rezaei, Clinical Immunology, Academic Press, 2023; 599-674, https://doi.org/10.1016/B978-0-12-818006-8.00008-6.
3. Li Q, Lan P. Activation of immune signals during organ transplantation. Signal Transduct Target Ther. 2023 Mar 11;8(1):110. doi: 10.1038/s41392-023-01377-9. PMID: 36906586; PMCID: PMC10008588.
4. Xiaojie Gan, Jian Gu, Zheng Ju, Ling Lu, Diverse Roles of Immune Cells in Transplant Rejection and Immune Tolerance, Engineering, 2022; 10, 44-56, https://doi.org/10.1016/j.eng.2021.03.029.
5. Amir Elalouf, Infections after organ transplantation and immune response, Transplant Immunology, 2023; 77, 101798. https://doi.org/10.1016/j.trim.2023.101798.
6. Tamargo CL, Kant S. Pathophysiology of Rejection in Kidney Transplantation. *Journal of Clinical Medicine*. 2023; 12(12):4130. https://doi.org/10.3390/jcm12124130
7. Ingulli, E. Mechanism of cellular rejection in transplantation. *Pediatr Nephrol* **25**, 61–74 (2010). https://doi.org/10.1007/s00467-008-1020-x
8. Etxebarria A, Díez-Martín E, Astigarraga E, Barreda-Gómez G. Role of the Immune System in Renal Transplantation, Types of Response, Technical Approaches and Current Challenges. *Immuno*. 2022; 2(4):548-570. https://doi.org/10.3390/immuno2040035
9. Ochando, J., Mulder, W.J.M., Madsen, J.C. *et al.* Trained immunity — basic concepts and contributions to immunopathology. *Nat Rev Nephrol* **19**, 23–37 (2023). https://doi.org/10.1038/s41581-022-00633-5
10. Waldmann H, Hilbrands R, Howie D, Cobbold S. Harnessing FOXP3+ regulatory T cells for transplantation tolerance. J Clin Invest. 2014 Apr;124(4):1439-45. doi: 10.1172/JCI67226. Epub 2014 Apr 1. PMID: 24691478; PMCID: PMC3973097.
11. Cassano A, Chong AS, Alegre ML. Tregs in transplantation tolerance: role and therapeutic potential. Front Transplant. 2023 Aug 30; 2:1217065. doi: 10.3389/frtra.2023.1217065. PMID: 38993904; PMCID: PMC11235334.
12. F. Braza, M. Durand, N. Degauque, S. Brouard, Regulatory T Cells in Kidney Transplantation: New Directions?, American Journal of Transplantation, 2015; 15, (9): 2288-2300. https://doi.org/10.1111/ajt.13395.
13. Stuart J Knechtle, Knowledge about transplantation tolerance gained in primates, Current Opinion in Immunology, 2000; 12(5): 552-556. https://doi.org/10.1016/S0952-7915(00)00137-0.
14. Oparaugo NC, Ouyang K, Nguyen NPN, Nelson AM, Agak GW. Human Regulatory T Cells: Understanding the Role of Tregs in Select Autoimmune Skin Diseases and Post-Transplant Nonmelanoma Skin Cancers. Int J Mol Sci. 2023 Jan 12;24(2):1527. doi: 10.3390/ijms24021527. PMID: 36675037; PMCID: PMC9864298.
15. Okeke EB, Uzonna JE. The Pivotal Role of Regulatory T Cells in the Regulation of Innate Immune Cells. Front Immunol. 2019 Apr 9; 10:680. doi: 10.3389/fimmu.2019.00680. PMID: 31024539; PMCID: PMC6465517.
16. Xianmei Li, Fenghua Zhang, Nan Wu, Ding Ye, Yaqing Wang, Xiaofan Zhang, Yonghua Sun, Yong-An Zhang,A critical role of foxp3a-positive regulatory T cells in maintaining immune homeostasis in zebrafish testis development, Journal of Genetics and Genomics,2020; 47(9):547-561, https://doi.org/10.1016/j.jgg.2020.07.006.
17. Sakaguchi, S. Regulatory T cells. *Springer Semin Immun* **28**, 1–2 (2006). https://doi.org/10.1007/s00281-006-0043-2
18. Sojka DK, Huang YH, Fowell DJ. Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target. Immunology. 2008 May;124(1):13-22. doi: 10.1111/j.1365-2567.2008.02813.x. Epub 2008 Mar 14. PMID: 18346152; PMCID: PMC2434375.
19. Kitz A, Dominguez-Villar M. Molecular mechanisms underlying Th1-like Treg generation and function. Cell Mol Life Sci. 2017 Nov;74(22):4059-4075. doi: 10.1007/s00018-017-2569-y. Epub 2017 Jun 17. PMID: 28624966; PMCID: PMC7079789.
20. Dhawan M, Rabaan AA, Alwarthan S, Alhajri M, Halwani MA, Alshengeti A, Najim MA, Alwashmi ASS, Alshehri AA, Alshamrani SA, et al. Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities with a Special Focus on Long COVID. *Vaccines*. 2023; 11(3):699. https://doi.org/10.3390/vaccines11030699
21. Li, C., Jiang, P., Wei, S. *et al.* Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. *Mol Cancer* **19**, 116 (2020). https://doi.org/10.1186/s12943-020-01234-1
22. Walker LS, Sansom DM. Confusing signals: recent progress in CTLA-4 biology. Trends Immunol. 2015 Feb;36(2):63-70. doi: 10.1016/j.it.2014.12.001. Epub 2015 Jan 9. PMID: 25582039; PMCID: PMC4323153.

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

23. Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y. CTLA-4 in Regulatory T Cells for Cancer Immunotherapy. Cancers (Basel). 2021 Mar 22;13(6):1440. doi: 10.3390/cancers13061440. PMID: 33809974; PMCID: PMC8005092.
24. Lucy S.K. Walker,Treg and CTLA-4: Two intertwining pathways to immune tolerance,Journal of Autoimmunity,2013; 45, 49-57. https://doi.org/10.1016/j.jaut.2013.06.006.
25. Goswami TK, Singh M, Dhawan M, Mitra S, Emran TB, Rabaan AA, Mutair AA, Alawi ZA, Alhumaid S, Dhama K. Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders - Advances and challenges. Hum Vaccin Immunother. 2022 Dec 31;18(1):2035117. doi: 10.1080/21645515.2022.2035117. Epub 2022 Mar 3. PMID: 35240914; PMCID: PMC9009914.
26. Kazem Mashayekhi, Khashayarsha Khazaie, William A. Faubion, Gloria B. Kim, Biomaterial-enhanced treg cell immunotherapy: A promising approach for transplant medicine and autoimmune disease treatment, Bioactive Materials, 2024; 37, 269-298. https://doi.org/10.1016/j.bioactmat.2024.03.030.
27. Ziyu Liu, Jiajun Zhou, Shihui Wu, Zhihong Chen, Shuhong Wu, Ling Chen, Xiao Zhu, Zesong Li, Why Treg should be the focus of cancer immunotherapy: The latest thought, Biomedicine & Pharmacotherapy, 2023; 168, 115142. https://doi.org/10.1016/j.biopha.2023.115142.
28. Wang, J., Zhao, X. & Wan, Y.Y. Intricacies of TGF-β signaling in Treg and Th17 cell biology. *Cell Mol Immunol* **20**, 1002–1022 (2023). https://doi.org/10.1038/s41423-023-01036-7
29. Harris F, Berdugo YA, Tree T. IL-2-based approaches to Treg enhancement. Clin Exp Immunol. 2023 Mar 16;211(2):149-163. doi: 10.1093/cei/uxac105. PMID: 36399073; PMCID: PMC10019135.
30. Muhammad, S., Fan, T., Hai, Y. *et al.* Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies. *Mol Cancer* **22**, 121 (2023). https://doi.org/10.1186/s12943-023-01826-7
31. Hu, A., Sun, L., Lin, H. *et al.* Harnessing innate immune pathways for therapeutic advancement in cancer. *Sig Transduct Target Ther* **9**, 68 (2024). https://doi.org/10.1038/s41392-024-01765-9
32. Kosmaczewska A. Low-Dose Interleukin-2 Therapy: A Driver of an Imbalance between Immune Tolerance and Autoimmunity. *International Journal of Molecular Sciences.* 2014; 15(10):18574-18592. https://doi.org/10.3390/ijms151018574
33. Kosmaczewska A. Low-Dose Interleukin-2 Therapy: A Driver of an Imbalance between Immune Tolerance and Autoimmunity. *International Journal of Molecular Sciences.* 2014; 15(10):18574-18592. https://doi.org/10.3390/ijms151018574
34. Shevyrev D, Tereshchenko V. Treg Heterogeneity, Function, and Homeostasis. Front Immunol. 2020 Jan 14;10:3100. doi: 10.3389/fimmu.2019.03100. PMID: 31993063; PMCID: PMC6971100.
35. Blinova VG, Zhdanov DD. Many Faces of Regulatory T Cells: Heterogeneity or Plasticity? Cells. 2024 Jun 1;13(11):959. doi: 10.3390/cells13110959. PMID: 38891091; PMCID: PMC11171907.

CITE AS: Awafung Emmanuel Adie (2024). Harnessing Regulatory T Cells for Immune Modulation in Transplantation Tolerance. NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY, 5(3): 38-42. https://doi.org/10.59298/NIJPP/2024/5338420